Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefurulimab PK/PD, safety and efficacy in pediatric AChR+ generalized myasthenia gravis
jRCT2031250602Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of gefurulimab in generalized myasthenia gravis (gMG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Pharmacokinetics of gefurulimab and Pharmacodynamics of gefurulimab. Started Jan 2026; status: recruiting.
02
Drugs
gefurulimab
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on jRCT2031250602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250602.